New hope for hard-to-treat colorectal cancer: drug duo targets stubborn tumors
NCT ID NCT04599140
First seen Jan 26, 2026 · Last updated Apr 25, 2026 · Updated 12 times
Summary
This study tests a combination of two drugs—SX-682 and nivolumab—in people with a specific type of advanced colorectal cancer that has spread or cannot be removed. The cancer must have a RAS mutation and be microsatellite stable (MSS), which often makes it harder to treat. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 51 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III RECTAL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.